PRME vs. NTLA

Last updated Apr 1, 2026

Compare and contrast key facts about Prime Medicine Inc. Common Stock (PRME) and Intellia Therapeutics, Inc. (NTLA).

Performance

PRME vs. NTLA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Prime Medicine Inc. Common Stock (PRME) and Intellia Therapeutics, Inc. (NTLA). The values are adjusted to include any dividend payments, if applicable.

PRME vs. NTLA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
PRME Prime Medicine Inc. Common Stock	0.29%	18.84%	-67.04%	-52.31%	20.88%
NTLA Intellia Therapeutics, Inc.	42.60%	-22.90%	-61.76%	-12.61%	-29.36%

Fundamentals

Market Cap PRME : $517.68M NTLA : $1.39B
EPS PRME : -$1.38 NTLA : -$3.84
PB Ratio PRME : 4.28 NTLA : 2.07
Total Revenue (TTM) PRME : $4.63M NTLA : $0.00
Gross Profit (TTM) PRME : $0.00 NTLA : -$34.30M
EBITDA (TTM) PRME : -$195.76M NTLA : -$322.22M

Returns By Period

In the year-to-date period, PRME achieves a 0.29% return, which is significantly lower than NTLA's 42.60% return.

PRME

• 1D: 10.48%
• 1M: -24.68%
• YTD: 0.29%
• 6M: -37.18%
• 1Y: 74.87%
• 3Y*: -34.35%
• 5Y*: —
• 10Y*: —

NTLA

• 1D: 10.04%
• 1M: -6.97%
• YTD: 42.60%
• 6M: -25.77%
• 1Y: 80.31%
• 3Y*: -29.93%
• 5Y*: -30.67%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

PRME vs. NTLA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRME

PRME Risk / Return Rank: 68
PRME Sharpe Ratio Rank: 65
PRME Sortino Ratio Rank: 74
PRME Omega Ratio Rank: 66
PRME Calmar Ratio Rank: 70
PRME Martin Ratio Rank: 63

NTLA

NTLA Risk / Return Rank: 66
NTLA Sharpe Ratio Rank: 70
NTLA Sortino Ratio Rank: 71
NTLA Omega Ratio Rank: 73
NTLA Calmar Ratio Rank: 61
NTLA Martin Ratio Rank: 58

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PRME vs. NTLA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PRME	NTLA	Difference
Sharpe ratio Return per unit of total volatility	0.67	0.80	-0.13
Sortino ratio Return per unit of downside risk	1.78	1.60	+0.18
Omega ratio Gain probability vs. loss probability	1.19	1.23	-0.04
Calmar ratio Return relative to maximum drawdown	1.42	0.83	+0.59
Martin ratio Return relative to average drawdown	2.29	1.48	+0.81
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PRME vs. NTLA - Sharpe Ratio Comparison

The current PRME Sharpe Ratio is 0.67, which is comparable to the NTLA Sharpe Ratio of 0.80. The chart below compares the historical Sharpe Ratios of PRME and NTLA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	PRME	NTLA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.67	0.80	-0.13
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.38	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.39	-0.07	-0.32

Correlation

The correlation between PRME and NTLA is 0.58, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

PRME vs. NTLA - Dividend Comparison

Neither PRME nor NTLA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

PRME vs. NTLA - Drawdown Comparison

The maximum PRME drawdown since its inception was -94.55%, roughly equal to the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for PRME and NTLA.

Drawdown Indicators

	PRME	NTLA	Difference
Max Drawdown Largest peak-to-trough decline	-94.55%	-96.45%	+1.90%
Max Drawdown (1Y) Largest decline over 1 year	-52.77%	-71.27%	+18.50%
Max Drawdown (5Y) Largest decline over 5 years	—	-96.45%	—
Current Drawdown Current decline from peak	-83.52%	-92.75%	+9.23%
Average Drawdown Average peak-to-trough decline	-64.37%	-56.41%	-7.96%
Ulcer Index Depth and duration of drawdowns from previous peaks	32.70%	39.85%	-7.15%

Volatility

PRME vs. NTLA - Volatility Comparison

Prime Medicine Inc. Common Stock (PRME) and Intellia Therapeutics, Inc. (NTLA) have volatilities of 21.00% and 21.45%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PRME	NTLA	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.00%	21.45%	-0.45%
Volatility (6M) Calculated over the trailing 6-month period	66.76%	84.99%	-18.23%
Volatility (1Y) Calculated over the trailing 1-year period	112.28%	102.02%	+10.26%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	91.01%	80.71%	+10.30%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	91.01%	78.28%	+12.73%

Financials